The complexity of TME is also reflected by the stimulatory factors, inhibitory factors, and positive correlations among immune checkpoints in the same group of patients.TMB has now been shown to be a useful biomarker for selective immune checkpoint blockade in a wide range of cancers16, and MSI has been confirmed by many authors as a prognostic indicator and a predictor of treatment efficacy29, 30, and the results show that IGFL2 in COAD, THYM, UCEC, DLBC, HNSC, LUAD, LUSC, SARC, UVM may serve as biomarkers for tumor immunotherapy. The gene discussed is IGFL2; the disease is neoplasm.